Payment overview · 2025
General Payments
$424.57
23 reported records · 11 companies
Healthcare provider profile · identity verified
Jayprakash D Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JEMISON, AL · NPI 1083699334
Verified facts
What the public records show
CMS Open Payments records show Jayprakash D Patel, MD received $424.57 in general payments during 2025 across 23 reported records.
Esperion Therapeutics, Inc. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $89.19 | 21.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.34 | 16.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.27 | 11.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.68 | 10.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.45 | 9.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.62 | 8.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.43 | 7.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.71 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.68 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.68 | 3.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.52 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.57 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $89.19 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.07 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| VIIBRYD Normalized: viibryd |
Drug | ABBVIE INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 167 |
| Lisinopril | Lisinopril | 514 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 451 | 132 |
| Tizanidine Hcl | Tizanidine Hcl | 393 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 112 |
| Meloxicam | Meloxicam | 375 | 127 |
| Metformin Hcl | Metformin Hcl | 336 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 273 | 73 |
| Omeprazole | Omeprazole | 272 | 84 |
| Glimepiride | Glimepiride | 249 | 69 |
| Gabapentin | Gabapentin | 238 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 71 |
| Trazodone Hcl | Trazodone Hcl | 215 | 67 |
| Losartan Potassium | Losartan Potassium | 213 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 54 |
| Buspirone Hcl | Buspirone Hcl | 177 | 50 |
| Simvastatin | Simvastatin | 177 | 51 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 172 | 123 |
| Amoxicillin | Amoxicillin | 171 | 125 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 48 |
| Azithromycin | Azithromycin | 166 | 114 |
| Alprazolam | Alprazolam | 163 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 50 |
| Fenofibrate | Fenofibrate | 150 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 32 |
| Eliquis | Apixaban | 114 | 30 |
| Famotidine | Famotidine | 113 | 43 |
| Furosemide | Furosemide | 113 | 56 |
| Prednisone | Prednisone | 113 | 65 |
| Carvedilol | Carvedilol | 110 | 36 |
| Potassium Chloride | Potassium Chloride | 108 | 42 |
| Montelukast Sodium | Montelukast Sodium | 97 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 28 |
| Tramadol Hcl | Tramadol Hcl | 84 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Colestipol Hcl | Colestipol Hcl | 75 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 13 |
| Cephalexin | Cephalexin | 73 | 50 |
| Atenolol | Atenolol | 70 | 19 |
| Donepezil Hcl | Donepezil Hcl | 69 | 30 |
| Sertraline Hcl | Sertraline Hcl | 68 | 22 |
| Allopurinol | Allopurinol | 66 | 20 |
| Alendronate Sodium | Alendronate Sodium | 63 | 25 |
| Lorazepam | Lorazepam | 63 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 18 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 59 | 17 |
| Fluconazole | Fluconazole | 57 | 33 |
| Finasteride | Finasteride | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 15 |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 48 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 24 |
| Celecoxib | Celecoxib | 42 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 22 |
| Primidone | Primidone | 36 | 11 |
| Metronidazole | Metronidazole | 34 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Spironolactone | Spironolactone | 33 | 14 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Colchicine | Colchicine | 29 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 13 |
| Ramipril | Ramipril | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.57 · 23 records | Esperion Therapeutics, Inc. | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, VIIBRYD, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error